CRL
Charles River Laboratories International, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$289.28
−1.39%Aug 11, 2026, 09:30 UTC
Charles River Laboratories International's stock reached a new 52-week high on Tuesday, trading as high as $277.07.
Source:Aug 5, 2026, 00:00 UTC
Charles River Laboratories International, Inc. repurchased $100 million of its common stock during the second quarter of 2026 at an average price of $174 per share.
Aug 5, 2026, 00:00 UTC
Charles River Laboratories International, Inc. reported its second quarter 2026 financial results, with total revenue of $1.00 billion, a GAAP net loss of $1.5 million, and non-GAAP diluted EPS of $3.02.
Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jul 13, 2026, 12:00 UTC
Charles River Laboratories announced a collaboration with Arovella Therapeutics to provide GMP NGS services for cell characterization, supporting Arovella's iNKT cell therapy platform for cancer treatment.
Jun 25, 2026, 05:00 UTC
Eli Lilly started a collaboration with about 100 smaller biotechs, including Charles River Laboratories, to work with AI models in return for their data.
Source: